ClinicalTrials.gg
CompletedNCT04745026Updated Mar 30, 2025Results posted

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

A Phase 2 interventional study of GWP42003-P and Placebo in Autism Spectrum Disorder, sponsored by Jazz Pharmaceuticals. Completed at 23 sites in 6 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
163rd of 658
103 · median 50
Started
2021
with 63 others
Phase 2
101 of 773
15 open now
Registered
465th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 163rd largest by enrollment of the 658 interventional ones that give a count, is one of 64 that started in 2021, is one of 101 in phase 2, and was the 465th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 500 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

160 more — sign in →

All 165 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 349 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 294 (84%) stop at 75 or younger; 298 take children under 18; 92 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

This study will be conducted to evaluate the efficacy of GWP42003-P, compared with placebo, in reducing symptom severity in children with Autism Spectrum Disorder (ASD).

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Cannabidiol oral solution
  • CBD-OS
  • GWP42003-P
  • Children
  • Adolescents
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant weight is at least 12 kilograms (kg).
  • Participants (if possessing adequate understanding, in the investigator's opinion) and their parent(s)/legal representative are willing and able to give informed assent and consent for participation in the trial.
  • Participant and their caregiver are willing and able (in the investigator's opinion) to comply with all trial requirements.
  • Participant has a diagnosis of Autism Spectrum Disorder (ASD) as per , 5th Edition (DSM-5) criteria for ASD, confirmed by Autism Diagnostic Observational Schedule (ADOS-2) criteria (conducted within 2 years at the trial site or at screening by a qualified assessor). Note: During special circumstances (e.g., COVID-19 pandemic) where the ADOS-2 cannot be performed due to site restrictions (e.g., mandatory use of face masks) and an ADOS- 2 conducted within 2 years at the trial site by a qualified assessor is not available, eligibility can be confirmed using: 1) an ADOS-2 performed within 2 years by a qualified assessor (external to the site); 2) if 1) is not available, eligibility may be confirmed using the Autism Diagnostic Interview, Revised (ADI-R) at screening.
  • Clinical Global Impressions - Improvement Scale (CGI-S) ≥ 4 (moderately ill) at screening and randomization.
  • Intelligence quotient (IQ) ≥ 70 at screening, or measured within 1 year of screening, using Wechsler Abbreviated Scale of Intelligence Scale Second Edition (WASI-II).
  • All medications or interventions (including psychosocial interventions, dietary supplements, probiotics, speech therapy, etc.) for ASD related symptoms must have been stable for 4 weeks prior to screening and randomization, and the patient/caregiver should be willing to maintain a stable regimen throughout the trial.
  • Participants must have the ability to swallow the medicinal product (IMP), provided as a liquid solution.
  • Participant and/or parent(s)/legal representative is willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
  • Participant and/or parent(s)/legal representative is/are willing to allow the participant's primary care practitioner (if they have one) and consultant (if they have one) to be notified of participation in the trial if the primary care practitioner/consultant is different from the investigator.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of bipolar disorder, psychosis, schizophrenia, schizoaffective disorder, or major depression (participants with depression in remission may be included)
  • Has a diagnosis other than ASD that dominates the clinical presentation (e.g., Attention Deficit Hyperactivity Disorder [ADHD])
  • Has a progressive neurological condition
  • Seizures in the past 24 weeks
  • Changes in anticonvulsive therapy within the last 12 weeks
  • Currently taking more than 2 anti-epileptic drugs (AEDs)
  • Taking sirolimus, everolimus, temsirolimus, or tacrolimus
  • Taking clobazam
  • Taking omeprazole, lansoprazole, tolbutamide, or warfarin
  • Taking repaglinide, pioglitazone, rosiglitazone, montelukast, bupropion, or efavirenz
  • Currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex®, or Epidiolex®) within the 12 weeks prior to screening and is unwilling to abstain for the duration of the trial
  • Participant has any known or suspected to cannabinoids or any of the of the IMP, such as sesame oil.
  • Participant has moderately impaired hepatic function at screening, defined as serum (ALT) or aspartate aminotransferase (AST) > 2 × (ULN) or total (TBL) > 2 × ULN. This criterion can only be confirmed once the laboratory results are available; participants enrolled into the trial who are later found to meet this criterion must be screen-failed.
  • Participant is male and fertile (i.e., after puberty unless permanently sterile by bilateral orchidectomy) unless willing to ensure that they use male (condom) or remain sexually abstinent during the trial and for 12 weeks thereafter.
  • Participant is female and of (i.e., following menarche and until becoming for ≥ 12 consecutive months unless permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) unless willing to ensure that they use a highly effective method of birth control (e.g., hormonal contraception, intrauterine device/hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence) during the trial and for 12 weeks thereafter.
  • Female participant who is pregnant (positive pregnancy test), lactating or planning pregnancy during the course of the trial or within 12 weeks thereafter.
  • Participant has received an IMP within the 12 weeks prior to the screening visit.
  • Participant had brain surgery or traumatic brain injury within 1 year of screening.
  • Participant has any other significant disease or disorder which, in the opinion of the investigator, may either put the participant, other participants, or site staff at risk because of participation in the trial, may influence the result of the trial, or may affect the participant's ability to take part in the trial.
  • Any abnormalities identified following a physical examination of the participant that, in the opinion of the investigator, would jeopardize the safety of the participant if they took part in the trial
  • Any history of suicidal behavior (lifelong) or any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last 4 weeks or at screening or randomization
  • Participant has donated blood during the past 12 weeks and is unwilling to abstain from donation of blood during the trial.
  • Participant has any known or suspected history of alcohol or substance abuse or positive drugs of abuse test at screening (not justified by a known concurrent medication).
  • Participant has previously been randomized into this trial.
  • Participant has plans to travel outside their country of residence during the trial, unless the participant has confirmation that the IMP is permitted in the destination country/state
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    GWP42003-P 10 mg/kg/day

    Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive 5 milligrams per kilogram per day (mg/kg/day) GWP42003-P for 1 week and then 10 mg/kg/day GWP42003-P for 11 weeks.

    Drug: GWP42003-P

  • Placebo comparator
    Placebo

    Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive matching placebo for 12 weeks.

    Drug: Placebo

Interventions

  • GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)

    Also known as: Epidiolex®, cannabidiol, CBD-OS

  • DrugPlacebo

    Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Aberrant Behavior Checklist (ABC) Subscale Total Scores

    The caregiver-assessed ABC was designed to assess the presence and severity of various problem behaviors commonly observed in individuals diagnosed with intellectual and developmental disability. The checklist contains 5 subscales: Irritability (15 items); Social Withdrawal (16 items); Stereotypic Behavior (7 items); Hyperactivity/Noncompliance (16 items); and Inappropriate Speech (4 items). Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). The total score of all items for each subscale range from 0-45 (irritability), 0-48 (social withdrawal and hyperactivity/noncompliance), 0-21 (stereotypic behavior), and 0-12 (inappropriate speech) where higher scores indicate worse clinical outcome. The change from baseline to Week 4, Week 8, and Week 12 is reported with lower scores indicating better clinical outcome.

    Time frame: Baseline up to Week 12

  2. Change From Baseline in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores

    The VABS-3 scales assess what a person does, rather than what he or she can do. The Vineland-3 assesses adaptive behavior in 3 domains: Communication, Daily Living Skills, and Socialization. Each domain is comprised of 3 subdomains: receptive expression and written (communication); personal, domestic and community (daily living skills); Interpersonal relationships, play and leisure and copying skills (socialization). The adaptive behavior composite score is calculated as arithmetic mean of all 3 domain scores. The total score range is 20 to 140, where low scores indicate low (worst) clinical outcome and high scores indicate high (best) clinical outcome. The change from baseline in VABS-3 is being reported with positive values indicating a positive improvement in adaptive behavior.

    Time frame: Baseline up to Week 12

  3. Number of Patients Per Clinical Global Impression Improvement (CGI-I) Category

    The CGI-I is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The clinician is asked: Compared to the patient's condition at admission to the project, how much has the patient changed? This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Higher scores indicate worse clinical outcome. The number of patients in each CGI-I category is reported.

    Time frame: Day 85

  4. Change From Baseline in Clinical Global Impression Severity (CGI-S) Scores

    The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's experience with patients who have the same diagnosis. The clinician is asked: Considering your total clinical experience with this particular population, how ill is the patient at this time? This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Higher scores indicate worse outcome. The change from baseline in CGI-S scores is reported and lower mean scores indicate better outcome.

    Time frame: Baseline up to Week 12

Secondary outcomes

  1. Number of Participants Reporting Treatment-emergent Adverse Events

    A TEAE is one that started, or worsened in severity or seriousness, following the first dose of IMP. AEs were coded according to the Medical Dictionary for Regulatory Activities v24.0 dictionary.

    Time frame: Baseline up to Week 12

  2. Mean Change From Baseline in Hematology Clinical Laboratory Levels

    Time frame: Baseline up to Week 9 (end of taper/withdrawal)

  3. Mean Percentage Change From Baseline in Hematology Clinical Laboratory Levels

    Time frame: Baseline up to Week 9 (end of taper/withdrawal)

  4. Mean Change From Baseline in Hemoglobin Levels

    Time frame: Week 9 (end of taper/withdrawal)

  5. Mean Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Levels

    Time frame: Week 9 (end of taper/withdrawal)

  6. Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Levels

    Time frame: Week 9 (end of taper/withdrawal)

  7. Number of Patients With Clinically Significant Vital Sign Values

    Time frame: Post-baseline up to 12 weeks

  8. Number of Patients With Clinically Significant Physical Examination Procedure Findings

    Number of patients with abnormal physical exam findings are reported.

    Time frame: Baseline up to Day 85 post-baseline

  9. Number of Patients With Clinically Significant 12-lead Electrocardiogram Findings

    Time frame: Baseline up to Day 85 post-baseline

  10. Number of Participants Reporting Suicidal Ideation or Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS rating scale results since last visit is reported. The presence/absence of any suicidal ideation or behavior is scored based on yes/no responses. The overall number of participants reporting suicidal ideation or behavior is being reported.

    Time frame: Baseline up to Day 92

07

Results

Posted Mar 30, 2025

Participant flow

A total of 191 patients were screened for this study. Of those 191 patients, 103 patients met all inclusion criteria and no exclusion criteria were enrolled in the study and randomized to treatment at 24 centers in the United States, Canada, Spain, United Kingdom, and Australia.

Participant flow — Overall Study
MilestoneGWP42003-PPlacebo
Started4954
Completed3641
Not completed1313
Withdrew: Physician decision10
Withdrew: Adverse event22
Withdrew: Protocol violation13
Withdrew: Lost to follow-up43
Withdrew: Withdrawal by subject55

Outcome measures

PrimaryChange From Baseline in Aberrant Behavior Checklist (ABC) Subscale Total Scores

The caregiver-assessed ABC was designed to assess the presence and severity of various problem behaviors commonly observed in individuals diagnosed with intellectual and developmental disability. The checklist contains 5 subscales: Irritability (15 items); Social Withdrawal (16 items); Stereotypic Behavior (7 items); Hyperactivity/Noncompliance (16 items); and Inappropriate Speech (4 items). Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). The total score of all items for each subscale range from 0-45 (irritability), 0-48 (social withdrawal and hyperactivity/noncompliance), 0-21 (stereotypic behavior), and 0-12 (inappropriate speech) where higher scores indicate worse clinical outcome. The change from baseline to Week 4, Week 8, and Week 12 is reported with lower scores indicating better clinical outcome.

Time frame:
Baseline up to Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Aberrant Behavior Checklist (ABC) Subscale Total Scores
score on a scaleGWP42003-PPlacebo
ABC-Irritability, Week 4-6.35 ± 7.98-5.41 ± 7.16
ABC-Irritability, Week 8-6.67 ± 8.63-8.05 ± 9.12
ABC-Irritability, Week 12-6.97 ± 9.68-8.57 ± 10.10
ABC-Social Withdrawal, Week 4-2.53 ± 5.61-2.92 ± 5.24
ABC-Social Withdrawal, Week 8-3.81 ± 6.76-4.74 ± 6.25
ABC-Social Withdrawal, Week 12-3.74 ± 6.21-4.51 ± 5.95
ABC-Stereotypic Behavior, Week 4-2.10 ± 4.24-1.39 ± 3.24
ABC-Stereotypic Behavior, Week 8-1.92 ± 3.99-1.98 ± 4.05
ABC-Stereotypic Behavior, Week 12-1.88 ± 3.63-2.31 ± 4.03
ABC-Hyperactivity/Noncompliance, Week 4-5.73 ± 8.08-4.55 ± 8.15
ABC-Hyperactivity/Noncompliance, Week 8-6.39 ± 9.15-7.42 ± 9.06
ABC-Hyperactivity/Noncompliance, Week 12-6.74 ± 10.62-8.77 ± 9.94
ABC-Inappropriate Speech, Week 4-2.13 ± 2.88-0.88 ± 2.07
ABC-Inappropriate Speech, Week 8-1.58 ± 2.74-1.44 ± 2.73
ABC-Inappropriate Speech, Week 12-1.94 ± 2.93-1.51 ± 2.97
Statistical analysis
  • GWP42003-P vs Placebo · Mixed models for repeated measures · p = =0.085 (Randomization factors, baseline score, visit, treatment arm, visit by treatment arm (fixed), and visit repeated within each patient (repeated).) · Least square mean difference: 3.37 · 95% CI -0.48 to 7.21
  • GWP42003-P vs Placebo · Mixed models for repeated measures · p = =0.3107 · Least square mean difference: 1.14 · 95% CI -1.08 to 3.36Randomization factors, baseline score, visit, treatment arm, visit by treatment arm (fixed), and visit repeated within each patient (repeated).
  • GWP42003-P vs Placebo · Mixed models for repeated measures · p = =0.9513 · Least square mean difference: 0.04 · 95% CI -1.34 to 1.42Randomization factors, baseline score, visit, treatment arm, visit by treatment arm (fixed), and visit repeated within each patient (repeated).
  • GWP42003-P vs Placebo · Mixed models repeated measures · p = =0.305 · Least square mean difference: 2.01 · 95% CI -1.86 to 5.88Randomization factors, baseline score, visit, treatment arm, visit by treatment arm (fixed), and visit repeated within each patient (repeated).
  • GWP42003-P vs Placebo · Mixed models repeated measures · p = =0.4754 · Least square mean difference: -0.37 · 95% CI -1.4 to 0.66Randomization factors, baseline score, visit, treatment arm, visit by treatment arm (fixed), and visit repeated within each patient (repeated).
PrimaryChange From Baseline in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores

The VABS-3 scales assess what a person does, rather than what he or she can do. The Vineland-3 assesses adaptive behavior in 3 domains: Communication, Daily Living Skills, and Socialization. Each domain is comprised of 3 subdomains: receptive expression and written (communication); personal, domestic and community (daily living skills); Interpersonal relationships, play and leisure and copying skills (socialization). The adaptive behavior composite score is calculated as arithmetic mean of all 3 domain scores. The total score range is 20 to 140, where low scores indicate low (worst) clinical outcome and high scores indicate high (best) clinical outcome. The change from baseline in VABS-3 is being reported with positive values indicating a positive improvement in adaptive behavior.

Time frame:
Baseline up to Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores
score on a scaleGWP42003-PPlacebo
Week 42.97 ± 6.700.99 ± 9.29
Week 83.69 ± 10.823.54 ± 8.83
Week 124.85 ± 8.835.55 ± 10.42
Statistical analysis
  • GWP42003-P vs Placebo · Mixed models for repeated measures · p = =0.8506 · Least square mean difference: 0.45 · 95% CI -4.26 to 5.15Randomization factors, baseline score, visit, treatment arm, visit by treatment arm (fixed), and visit repeated within each patient (repeated).
PrimaryNumber of Patients Per Clinical Global Impression Improvement (CGI-I) Category

The CGI-I is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The clinician is asked: Compared to the patient's condition at admission to the project, how much has the patient changed? This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Higher scores indicate worse clinical outcome. The number of patients in each CGI-I category is reported.

Time frame:
Day 85
Reported as:
Count of participants · Participants
Number of Patients Per Clinical Global Impression Improvement (CGI-I) Category
ParticipantsGWP42003-PPlacebo
Minimally improved1314
Much improved1211
No change911
Much worse01
Very much improved01
Minimally worse00
Very much worse00
Statistical analysis
  • GWP42003-P vs Placebo · Regression, Logistic · p = =0.7087 · Odds ratio (or): 1.22 · 95% CI 0.43 to 3.51Includes treatment arm, randomization variables and baseline score (CGI-S) covariates. Responders achieved a score of 1 or 2 at post-baseline visits.
PrimaryChange From Baseline in Clinical Global Impression Severity (CGI-S) Scores

The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's experience with patients who have the same diagnosis. The clinician is asked: Considering your total clinical experience with this particular population, how ill is the patient at this time? This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Higher scores indicate worse outcome. The change from baseline in CGI-S scores is reported and lower mean scores indicate better outcome.

Time frame:
Baseline up to Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scores
score on a scaleGWP42003-PPlacebo
Week 4-0.33 ± 0.61-0.31 ± 0.69
Week 8-0.50 ± 0.68-0.48 ± 0.92
Week 12-0.55 ± 0.85-0.63 ± 1.10
Statistical analysis
  • GWP42003-P vs Placebo · Cochran-Mantel-Haenszel · p = =0.6108
SecondaryNumber of Participants Reporting Treatment-emergent Adverse Events

A TEAE is one that started, or worsened in severity or seriousness, following the first dose of IMP. AEs were coded according to the Medical Dictionary for Regulatory Activities v24.0 dictionary.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-emergent Adverse Events
ParticipantsGWP42003-PPlacebo
TEAE2724
Non-TEAE2532
Treatment-related TEAE610
Serious TEAE21
Serious Treatment-related TEAE00
TEAE leading to study intervention withdrawal21
Treatment-related TEAE leading to drug withdrawal11
TEAE leading to withdrawal22
TEAE leading to death00
SecondaryMean Change From Baseline in Hematology Clinical Laboratory Levels
Time frame:
Baseline up to Week 9 (end of taper/withdrawal)
Reported as:
Mean · 10^9 cells/L
Mean Change From Baseline in Hematology Clinical Laboratory Levels
10^9 cells/LGWP42003-PPlacebo
Week 9: Basophils-0.01 ± 0.030 ± 0.03
Week 9: Eosinophils-0.09 ± 0.3110 ± 0.40
Week 9: Lymphocytes0.04 ± 0.70-0.20 ± 0.68
Week 9: Monocytes-0.01 ± 0.15-0.01 ± 0.19
Week 9: Neutrophils0.04 ± 1.80-0.01 ± 1.26
Week 9: Platelets-9.43 ± 34.508.43 ± 52.13
Week 9: Leukocytes-0.02 ± 1.87-0.23 ± 1.79
SecondaryMean Percentage Change From Baseline in Hematology Clinical Laboratory Levels
Time frame:
Baseline up to Week 9 (end of taper/withdrawal)
Reported as:
Mean · percentage change from baseline
Mean Percentage Change From Baseline in Hematology Clinical Laboratory Levels
percentage change from baselineGWP42003-PPlacebo
Week 9: Basophils/Leukocytes-0.07 ± 0.45-0.03 ± 0.42
Week 9: Eosinophils/Leukocytes-1.33 ± 5.370.22 ± 4.88
Week 9: Hematocrit-0.02 ± 2.190.43 ± 2.30
Week 9: Lymphocytes/Leukocytes1.05 ± 11.25-2.32 ± 8.26
Week 9: Monocytes/Leukocytes-0.16 ± 2.040.05 ± 1.86
Week 9: Neutrophils/Leukocytes0.49 ± 12.292.08 ± 8.89
SecondaryMean Change From Baseline in Hemoglobin Levels
Time frame:
Week 9 (end of taper/withdrawal)
Reported as:
Mean · g/dL
Mean Change From Baseline in Hemoglobin Levels
g/dLGWP42003-PPlacebo
Mean Change From Baseline in Hemoglobin Levels-0.06 ± 0.550.08 ± 0.65
SecondaryMean Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Levels
Time frame:
Week 9 (end of taper/withdrawal)
Reported as:
Mean · pg/cell
Mean Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Levels
pg/cellGWP42003-PPlacebo
Mean Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Levels0.13 ± 0.67-0.03 ± 0.72
SecondaryMean Change From Baseline in Erythrocyte Mean Corpuscular Volume Levels
Time frame:
Week 9 (end of taper/withdrawal)
Reported as:
Mean · fL
Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Levels
fLGWP42003-PPlacebo
Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Levels0.52 ± 2.320.03 ± 2.39
SecondaryNumber of Patients With Clinically Significant Vital Sign Values
Time frame:
Post-baseline up to 12 weeks
Reported as:
Count of participants · Participants
Number of Patients With Clinically Significant Vital Sign Values
ParticipantsGWP42003-PPlacebo
Increase in weight from baseline >7%713
Decrease in weight from baseline >7%22
Body temperature <36 degrees Celsius46
Body temperature >38 degrees Celsius10
Pulse rate <60 beats/min13
Pulse rate >100 beats/min74
Respiratory rate <12 breaths/min00
Respiratory rate >20 breaths/min1317
Systolic blood pressure <90 mmhg53
Systolic blood pressure >160 mmhg00
Diastolic blood pressure <50 mmhg32
Diastolic blood pressure >120 mmhg00
SecondaryNumber of Patients With Clinically Significant Physical Examination Procedure Findings

Number of patients with abnormal physical exam findings are reported.

Time frame:
Baseline up to Day 85 post-baseline
Reported as:
Count of participants · Participants
Number of Patients With Clinically Significant Physical Examination Procedure Findings
ParticipantsGWP42003-PPlacebo
Abdomen20
Cardiovascular00
Chest/lungs00
Dermatological33
Endocrine system00
Gastrointestinal00
General appearance02
HEENT01
Lymphatic00
Musculoskeletal/Extremities01
Neurological20
Other00
Genitourinary/Reproductive00
SecondaryNumber of Patients With Clinically Significant 12-lead Electrocardiogram Findings
Time frame:
Baseline up to Day 85 post-baseline
Reported as:
Count of participants · Participants
Number of Patients With Clinically Significant 12-lead Electrocardiogram Findings
ParticipantsGWP42003-PPlacebo
QTcB >450 msec74
QTcB >480 msec20
QTcB >500 msec10
SecondaryNumber of Participants Reporting Suicidal Ideation or Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS rating scale results since last visit is reported. The presence/absence of any suicidal ideation or behavior is scored based on yes/no responses. The overall number of participants reporting suicidal ideation or behavior is being reported.

Time frame:
Baseline up to Day 92
Reported as:
Count of participants · Participants
Number of Participants Reporting Suicidal Ideation or Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsGWP42003-PPlacebo
Suicidal ideation43
Wish to be dead33
Non-specific active suicidal thoughts21
Active suicidal ideation, no intent to act10
Active suicidal ideation, some intent to act00
Active suicidal ideation, specific plan/intent00
Suicidal behavior36
Actual attempt01
Interrupted attempt01
Aborted attempt00
Preparatory acts or behavior01
Suicidal behavior item01
Self-injurious behavior without suicidal intent35
Completed suicide00

Adverse events

Collected over Adverse event data were collected from baseline up to 14 days after last dose, up to approximately 12 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P0/49 (0%)2/49 (4.1%)14/49 (28.6%)
Placebo0/54 (0%)1/54 (1.9%)20/54 (37%)
Most frequent serious events
Most frequent serious events
EventGWP42003-PPlacebo
Suicidal ideationPsychiatric disorders1/490/54
COVID-19Infections and infestations1/491/54
Most frequent other events
Most frequent other events
EventGWP42003-PPlacebo
VomitingGastrointestinal disorders7/494/54
PyrexiaGeneral disorders0/495/54
IrritabilityPsychiatric disorders0/495/54
NasopharyngitisInfections and infestations4/490/54
HeadacheNervous system disorders3/494/54
CoughRespiratory, thoracic and mediastinal disorders3/490/54
FatigueGeneral disorders0/493/54
Upper respiratory tract infectionInfections and infestations0/493/54

Baseline characteristics

Demographic and baseline characteristics were assessed in the Safety Analysis Set.

Age, Categorical
Age, Categorical(Participants)GWP42003-PPlaceboTotal
<=18 years4954103
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)GWP42003-PPlaceboTotal
Mean11.1 ± 3.0210.8 ± 3.0110.9 ± 3
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-PPlaceboTotal
Female13720
Male364783
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GWP42003-PPlaceboTotal
American Indian or Alaska Native123
Asian123
Black or African American527
White324274
Multiple527
Unknown213
Not Reported123
Other213
WASI-II Intelligent Quotient Score
WASI-II Intelligent Quotient Score(score on a scale)GWP42003-PPlaceboTotal
Mean99.42 ± 18.03100.89 ± 17.16100.19 ± 17.49
Aberrant Behavior Checklist Irritability
Aberrant Behavior Checklist Irritability(score on a scale)GWP42003-PPlaceboTotal
Mean23.2 ± 7.3622.5 ± 8.7422.8 ± 8.09
Aberrant Behavior Checklist Social Withdrawal
Aberrant Behavior Checklist Social Withdrawal(score on a scale)GWP42003-PPlaceboTotal
Mean12.6 ± 8.6312.7 ± 9.1112.7 ± 8.85
Aberrant Behavior Checklist Stereotypic Behavior
Aberrant Behavior Checklist Stereotypic Behavior(score on a scale)GWP42003-PPlaceboTotal
Mean6.7 ± 5.086.7 ± 4.836.7 ± 4.92

4 further baseline measures are reported on the registry.

08

Study locations

23 sites
  • Southwest Autism Research and Resource Center (SARRRC)
    Phoenix, Arizona 85006, United States
  • UCSD School of Medicine
    La Jolla, California 92093, United States
  • UCLA Neuropsychiatric Institute
    Los Angeles, California 90024, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • APG Research, LLC
    Orlando, Florida 32803, United States
  • University of Louisville
    Louisville, Kentucky 40292, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Massachusetts General Hospital (Lurie Center for Autism)
    Lexington, Massachusetts 02421, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • Seattle Children's Research Institute
    Seattle, Washington 98105, United States
  • Monash Medical Centre
    Clayton, 03168, Australia
  • Queensland Children's Hospital
    South Brisbane, 4101, Australia
  • The Kids Clinic
    Ajax, Ontario L1Z0M1, Canada
  • Center for Pediatric Excellence
    Ottawa, Ontario K2G1W2, Canada
  • Klinik fur Psychiatrie, Psychotherapie und Psychosomatik im Kindes und Jugendalter
    Freiburg, 79104, Germany
  • Zentralinstitut fuer Seelische Gesundheit
    Mannheim, 68159, Germany
  • Instituto Global de Atencion Integral del Neurodesarrollo (IGAIN)
    Barcelona, 08007, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Corporacio Sanitaria Parc Tauli
    Sabadell, 08208, Spain
  • University of Glasgow Institute of Health and Wellbeing
    Glasgow, G128QQ, United Kingdom
  • Institute of Psychiatry, King's College London
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2023, 30 months.

Results were first posted in Mar 2025, 1 year 3 months after primary completion.

Of 82 phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 52. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Feb 9, 2021
StartActual
May 31, 2021
Primary completionActual
Dec 21, 2023
CompletionActual
Dec 21, 2023
Results first posted
Mar 30, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04745026
Responsible party
Sponsor
First posted
Feb 9, 2021
Start date
May 31, 2021
Primary completion
Dec 21, 2023
Completion
Dec 21, 2023
Results posted
Mar 30, 2025
Last update
Mar 30, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion